company background image
IPA

ImmunoPrecise Antibodies TSXV:IPA Stock Report

Last Price

CA$5.33

Market Cap

CA$132.4m

7D

0.8%

1Y

-49.2%

Updated

08 Aug, 2022

Data

Company Financials +
IPA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

IPA Stock Overview

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally.

ImmunoPrecise Antibodies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ImmunoPrecise Antibodies
Historical stock prices
Current Share PriceCA$5.33
52 Week HighCA$10.93
52 Week LowCA$4.52
Beta0.13
1 Month Change0.57%
3 Month Change-9.04%
1 Year Change-49.24%
3 Year Change87.02%
5 Year Change-11.17%
Change since IPO-17.36%

Recent News & Updates

Shareholder Returns

IPACA Life SciencesCA Market
7D0.8%0.8%-0.4%
1Y-49.2%-21.4%-1.2%

Return vs Industry: IPA underperformed the Canadian Life Sciences industry which returned -20.5% over the past year.

Return vs Market: IPA underperformed the Canadian Market which returned -2% over the past year.

Price Volatility

Is IPA's price volatile compared to industry and market?
IPA volatility
IPA Average Weekly Movement8.8%
Life Sciences Industry Average Movement11.0%
Market Average Movement10.8%
10% most volatile stocks in CA Market19.3%
10% least volatile stocks in CA Market4.4%

Stable Share Price: IPA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IPA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198385Jennifer Bathhttps://www.ipatherapeutics.com

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

ImmunoPrecise Antibodies Fundamentals Summary

How do ImmunoPrecise Antibodies's earnings and revenue compare to its market cap?
IPA fundamental statistics
Market CapCA$132.38m
Earnings (TTM)-CA$16.71m
Revenue (TTM)CA$19.36m

6.8x

P/S Ratio

-7.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IPA income statement (TTM)
RevenueCA$19.36m
Cost of RevenueCA$8.59m
Gross ProfitCA$10.77m
Other ExpensesCA$27.48m
Earnings-CA$16.71m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.67
Gross Margin55.63%
Net Profit Margin-86.29%
Debt/Equity Ratio1.7%

How did IPA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IPA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPA?

Other financial metrics that can be useful for relative valuation.

IPA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.4x
Enterprise Value/EBITDA-7.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IPA's PS Ratio compare to its peers?

IPA PS Ratio vs Peers
The above table shows the PS ratio for IPA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.6x
IOT Innovotech
4.4xn/aCA$6.4m
DOSE Rapid Dose Therapeutics
11.6xn/aCA$12.1m
STHZ StateHouse Holdings
1.4x58.4%CA$116.1m
VLNS Valens
1.1x21.3%CA$91.1m
IPA ImmunoPrecise Antibodies
6.8xn/aCA$132.4m

Price-To-Sales vs Peers: IPA is expensive based on its Price-To-Sales Ratio (6.8x) compared to the peer average (4.6x).


Price to Earnings Ratio vs Industry

How does IPA's PE Ratio compare vs other companies in the North American Life Sciences Industry?

Price-To-Sales vs Industry: IPA is expensive based on its Price-To-Sales Ratio (6.8x) compared to the North American Life Sciences industry average (5.4x)


Price to Sales Ratio vs Fair Ratio

What is IPA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IPA's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IPA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IPA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IPA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is ImmunoPrecise Antibodies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if IPA's forecast earnings growth is above the savings rate (1.6%).

Earnings vs Market: Insufficient data to determine if IPA's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if IPA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if IPA's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if IPA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IPA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has ImmunoPrecise Antibodies performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-19.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IPA is currently unprofitable.

Growing Profit Margin: IPA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPA is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare IPA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.9%).


Return on Equity

High ROE: IPA has a negative Return on Equity (-22.19%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is ImmunoPrecise Antibodies's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IPA's short term assets (CA$37.5M) exceed its short term liabilities (CA$9.3M).

Long Term Liabilities: IPA's short term assets (CA$37.5M) exceed its long term liabilities (CA$8.9M).


Debt to Equity History and Analysis

Debt Level: IPA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if IPA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IPA has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 29.1% each year.


Discover healthy companies

Dividend

What is ImmunoPrecise Antibodies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IPA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IPA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Jennifer Bath

4.5yrs

Tenure

CA$2,306,522

Compensation

Dr. Jennifer Lynne Bath, Ph D, has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018.Dr. Bath served as the Global Director of Client Relations at Ald...


CEO Compensation Analysis

Compensation vs Market: Jennifer's total compensation ($USD1.80M) is above average for companies of similar size in the Canadian market ($USD185.39K).

Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IPA's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: IPA's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IPA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.1%.


Top Shareholders

Company Information

ImmunoPrecise Antibodies Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: ImmunoPrecise Antibodies Ltd.
  • Ticker: IPA
  • Exchange: TSXV
  • Founded: 1983
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$132.380m
  • Shares outstanding: 24.84m
  • Website: https://www.ipatherapeutics.com

Number of Employees


Location

  • ImmunoPrecise Antibodies Ltd.
  • 3204–4464 Markham Street
  • Victoria
  • British Columbia
  • V8Z 7X8
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/08 00:00
End of Day Share Price2022/08/08 00:00
Earnings2022/04/30
Annual Earnings2022/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.